Figure 2 | Scientific Reports

Figure 2

From: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Figure 2

The PFS1 and OS of first-line EGFR-TKI in patients with advanced EGFR-mutant NSCLC. (A) The PFS1 of different EGFR-TKIs. (B) The PFS1 of different EGFR-TKIs in patients with exon 19 deletion. (C) The PFS1 of different EGFR-TKIs in patients with L858R. (D) The OS of different EGFR-TKIs. (E) The OS of different EGFR-TKIs in patients with exon 19 deletion. (F) The OS of different EGFR-TKIs in patients with L858R. PFS progression-free survival, OS overall survival, EGFR-TKI epidermal growth factor receptor–tyrosine kinase inhibitor, NSCLC non-small-cell lung cancer.

Back to article page